Medtronic plc (MDT) Announces FDA Approval for SmartGuard Algorithm as Automated Glycemic Controller

Medtronic plc (NYSE:MDT) is one of the 14 Tech Stocks to Sell Now According to Ken Fisher.

On September 2, 2025, Medtronic plc (NYSE:MDT) announced that the FDA cleared its SmartGuard algorithm as an interoperable automated glycemic controller, allowing its integration with Abbott’s Instinct sensor for type 1 diabetes. At the same time, the company’s MiniMed 780G system also received approval for adults with insulin-requiring type 2 diabetes.

With these achievements, Medtronic plc (NYSE:MDT) marks the first FDA-approved automated insulin delivery system with Meal Detection Technology for type 2 diabetes patients. These are supported by clinical trials, which show improved HbA1c levels, greater time in range, and reduced diabetes distress.

Thus, Medtronic plc (NYSE:MDT), in collaboration with Abbott, is advancing its plans to build a smarter dosing ecosystem designed to ease daily management, enhance flexibility, and improve quality of life for millions of patients with diabetes.

Medtronic plc (NYSE:MDT), a global healthcare technology leader, delivers innovative therapies and devices that treat over 70 health conditions. It is one of the stocks to sell.

While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 10 Must-Buy Canadian Stocks to Invest in.

Disclosure: None.